Symposium 11
3月27日［土］08:00-09:30
|
| |
| |
Front Lines of Optimal Management of Atherosclerosis Risks
|
|
|
| |
| |
|
|
| |
日本循環器学会は日本脳卒中学会と連携して、本邦で問題となっている脳卒中と循環器病克服5カ年計画を策定し、現在国を挙げて両疾患の発症予防のための対策が練られている。脳心血管病の基盤は粥状動脈硬化であり、その発症予防のためには粥状動脈硬化の種々の危険因子を如何に良好に管理するかが重要である。特に、動脈硬化と強く関連するリスクとしてのLDL-C管理の重要性は、スタチン、小腸コレステロールトランスポーター阻害薬、PCSK9阻害薬をはじめとするLDL-C低下薬の大規模臨床試験によって確立したと言えよう。しかしながら、LDL-Cを30 mg/dL程度まで低下させても、心血管イベントの発症は一部しか抑制されず、他のリスクを至適に管理する必要がある。本シンポジウムではLDL-Cの管理に加えて、それ以外の血清脂質・リポ蛋白（脂質異常症）、糖尿病・耐糖能異常、高血圧、メタボリックシンドローム、その他の至適管理の現状と各種薬物によるインターベンションの最新の成果について議論したい。更に、それらの議論を踏まえて、粥状動脈硬化の発症・進展予防のための今後の薬物開発の方向性についても考察する。
Japanese Circulation Society, in collaboration with the Japan Stroke Society, has set a “Five-Year Plan for Overcoming Cardiovascular Disease” to prevent stroke and cardiovascular diseases all over Japan. Cerebro- and cardiovascular diseases are caused by atherosclerosis of arteries and it is very important to control a variety of risk factors for atherosclerosis for their prevention. Especially, the importance of management of LDL-C has been established by a number of mega-trials of LDL-C lowering drugs such as statins, intestinal cholesterol transporter inhibitor, and PCSK9 inhibitors. However, even if serum LDL-C level is lowered to approximately 30 mg/dL, cardiovascular events are only partially prevented. Therefore, it may be crucial to appropriately control a variety of other risk factors. In this symposium, we will discuss, in addition to the current management of LDL-C, about the optimal strategies for treatment of dyslipidemia, diabetes/impaired glucose tolerance, hypertension, metabolic syndrome and other risk factors for atherosclerosis. Furthermore, we will also focus on the recent novel drug interventions for prevention of atherosclerotic cardiovascular diseases. Based upon these discussions, we will shed light into the directions for drug developments to attenuate atherogenesis and the progression of atherosclerosis.
|
|
|
| |
| |
|
|
| |
| |
 |
|
Shizuya Yamashita
Department of Cardiology, Rinku General Medical Center, Izumisano, Osaka
|
|
 |
|
Paul M Ridker
Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
|
|
|
| |
| |
| |
| |
|
|
| |
| |
|
|
Paul M Ridker
Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
|
|
 |
|
Hayato Tada
Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa
|
|
|
| |
| |
 |
|
Daisaku Masuda
Department of Cardiology, Rinku General Medical Center, Izumisano
|
|
 |
|
Yu Kataoka
Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center, Suita
|
|
|
| |
| |
 |
|
Takashi Shiroto
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai
|
|
 |
|
Haruki Sekiguchi
Department of Cardiology, Tokyo Women's Medical University, Tokyo
|
|
|
| |
| |
|
|